

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
仲 哲治	分子病態解析部門	教授	博士（医学）	臨床免疫学 腫瘍学	<p>①Uchida S., Serada S., Suzuki Y., Funajima E., Kitakami K., Dobashi K., Tamatani S., Sato Y., Beppu T., Ogasawara K., Naka T.: Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. <i>Neoplasia</i>. 50:100982.(2024)</p> <p>②Munekage E., Serada S., Tsujii S., Yokota K., Kiuchi K., Tominaga K., Fujimoto M., Kanda M., Uemura S., Namikawa T., Nomura T. Murakami T., Hanazaki K., Naka T.: A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. <i>Neoplasia</i>. 23(9):939-950. (2021)</p> <p>③Serada S., Fujimoto M., Terabe F., Iijima H., Shinzaki S., Matsuzaki S., Ohkawara T., Nezu R., Nakajima S., Kobayashi T., Plevy SE., Takehara T., Naka T.: Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. <i>Inflamm Bowel Dis</i>. 18(11):2169-79. (2012)</p> <p>④Serada S., Fujimoto M., Ogata A., Terabe F., Hirano T., Iijima H., Shinzaki S., Nishikawa T., Ohkawara T., Iwahori K., Ohguro N., Kishimoto T., Naka T.: iTRAQ-based proteomic identification of leucine rich alpha 2 glycoprotein (LRG) as a novel inflammatory biomarker in autoimmune diseases. <i>Ann Rheum Dis</i>. 69:770-774. (2010)</p> <p>⑤Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi O., Nomura S., Yoshida H., Nishikawa T., Terabe F., Ohkawara T., Takahashi T., Ripley B., Kimura A., Kishimoto T., Naka T.: IL-6 blockade inhibits the induction of myelin antigen specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. <i>Proc Natl Acad Sci U S A</i>. 105: 9041-9046. (2008)</p>
世良田 聡	分子病態解析部門	准教授	博士（理学）	分子生物学 標的治療 診断マーカー	<p>①Uchida S., Serada S., Suzuki Y., Funajima E., Kitakami K., Dobashi K., Tamatani S., Sato Y., Beppu T., Ogasawara K., Naka T.: Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. <i>Neoplasia</i>. 50:100982.(2024)</p> <p>②Munekage E., Serada S., Tsujii S., Yokota K., Kiuchi K., Tominaga K., Fujimoto M., Kanda M., Uemura S., Namikawa T., Nomura T. Murakami T., Hanazaki K., Naka T.: A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. <i>Neoplasia</i>. 23(9):939-950. (2021)</p> <p>③Serada S., Fujimoto M., Terabe F., Iijima H., Shinzaki S., Matsuzaki S., Ohkawara T., Nezu R., Nakajima S., Kobayashi T., Plevy SE., Takehara T., Naka T.: Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. <i>Inflamm Bowel Dis</i>. 18(11):2169-79. (2012)</p> <p>④Serada S., Fujimoto M., Ogata A., Terabe F., Hirano T., Iijima H., Shinzaki S., Nishikawa T., Ohkawara T., Iwahori K., Ohguro N., Kishimoto T., Naka T.: iTRAQ-based proteomic identification of leucine rich alpha 2 glycoprotein (LRG) as a novel inflammatory biomarker in autoimmune diseases. <i>Ann Rheum Dis</i>. 69:770-774. (2010)</p> <p>⑤Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi O., Nomura S., Yoshida H., Nishikawa T., Terabe F., Ohkawara T., Takahashi T., Ripley B., Kimura A., Kishimoto T., Naka T.: IL-6 blockade inhibits the induction of myelin antigen specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. <i>Proc Natl Acad Sci U S A</i>. 105: 9041-9046. (2008)</p>

クウィック あゆみ	分子病態解析部門	助手	社会健康医学修士 (専門職)	分子生物学	①山下 将司, 世良田 聡, クウィック あゆみ, 大河原 知治, 村田 興則, 細野 祐司, 伊藤 いづみ, 中屋 流石, 舟嶋 英治, 鈴木 悠地, 藤本 穰, 諏訪部 章, 仲 哲治.:シェーグレン症候群の疾患活動性評価におけるLRGの有用性の検討. 第33回日本リウマチ学会北海道・東北支部学術集会. (2023) ②Fujimoto M., Hosono Y., Serada S., Suzuki Y., Ohkawara T., Murata O., Quick A., Suzuki K., Kaneko Y., Takeuchi T., Naka T.: Leucine-rich $\alpha$ 2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Mod Rheumatol. Online ahead of print. (2023)
-----------	----------	----	-------------------	-------	--